QURE Form 4: CEO Kapusta exercises options and executes 10b5‑1 sales
Rhea-AI Filing Summary
uniQure N.V. insider Matthew C. Kapusta completed option exercises and multiple open-market sales under a 10b5-1 plan on September 24, 2025. The filing shows exercises of stock options at $7.53 (51,316 shares) and $6.22 (175,000 shares), producing reported acquisitions of 226,316 ordinary shares that increased his beneficial holdings to 877,770 shares before subsequent sales. The reporting person sold a series of shares the same day in multiple transactions at weighted-average prices reported between $39.20 and $45.30, resulting in a net decline to 651,454 shares beneficially owned after all reported sales. The transactions were made pursuant to a January 28, 2025 Rule 10b5-1 plan, and the Form 4 was signed by an attorney-in-fact on September 26, 2025.
Positive
- Transactions were executed under a documented Rule 10b5‑1 plan, reducing insider trading timing concerns
- Full disclosure of option vesting and weighted‑average sale price ranges is included in the filing
Negative
- Insider sold a material number of shares, reducing beneficial ownership from 877,770 to 651,454 shares
- Large-scale monetization at current market levels could be viewed negatively by some investors
Insights
TL;DR: Insider exercised low‑strike options and executed large, rule‑based sales the same day, materially reducing holdings but following a pre‑arranged plan.
The filing documents exercise of 226,316 option shares at strikes of $6.22 and $7.53 and immediate off‑market sales executed under a 10b5‑1 plan at weighted average prices ranging roughly $39.20–$45.30. This represents a significant monetization of equity accrued at much lower exercise prices and reduces reported beneficial ownership from a high of 877,770 to 651,454 shares. Because the trades were made under a pre‑established 10b5‑1 plan, they appear procedural rather than event‑driven, but the scale of sales is material relative to typical insider activity and could affect short‑term float and market perception.
TL;DR: Transactions comply with Rule 10b5‑1 and were disclosed on Form 4; governance procedures appear followed.
The filer discloses the adoption date of the 10b5‑1 plan (January 28, 2025) and includes standard footnotes about weighted average prices and vesting schedules. The presence of an attorney‑in‑fact signature and the detailed explanatory footnotes indicate adherence to disclosure protocols. From a governance perspective, this is routine compliance and transparent reporting of option exercises and scheduled sales, though stakeholders may note the sizeable reduction in insider ownership.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 51,316 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 175,000 | $0.00 | -- |
| Exercise | Ordinary Shares | 51,316 | $7.53 | $386K |
| Exercise | Ordinary Shares | 175,000 | $6.22 | $1.09M |
| Sale | Ordinary Shares | 51,316 | $39.59 | $2.03M |
| Sale | Ordinary Shares | 60,000 | $40.04 | $2.40M |
| Sale | Ordinary Shares | 49,978 | $40.68 | $2.03M |
| Sale | Ordinary Shares | 5,022 | $41.69 | $209K |
| Sale | Ordinary Shares | 60,000 | $45.10 | $2.71M |
Footnotes (1)
- The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on January 28, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.20 to $40.15. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.15. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.42 to $41.42 The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.56 to $41.76. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.30. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The Stock Option vested 25% on September 29, 2017 and 6.25% quarterly thereafter. Adjusted to reflect the exercise and sale of 7,501 option shares under the Reporting Person's 10b5-1 plan on February 19, 2020. The Stock Option vested 25% on March 14, 2018 and 6.25% quarterly thereafter.
